Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGL19D)

• Drug Name: Enzalutamide Drug Info
• Synonyms: MDV3100; Enzalutamide (AR inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]

• Cross-matching ID:
  PubChem CID: 15951529
  ChEBI ID: CHEMBL1082407
  CAS Number: CAS 915087-33-1
  TTD Drug ID: DMGL19D
  ACDINA Drug ID: D01051

Molecule-Related Drug Atlas

Drug(s) Targeting Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[5]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[6]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[7]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[8]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[9]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[10]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[11]
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[12]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[13]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[14]

Drug(s) Affected By Very long chain fatty acid elongase 7 (ELOVL7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[19]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]

Drug(s) Affected By Bone morphogenetic protein receptor type-1B (BMPR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[24]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[28]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[29]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[30]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[31]

Drug(s) Affected By Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[35]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[33]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[35]

Drug(s) Affected By RNA polymerase II elongation factor ELL2 (ELL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[38]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[40]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[45]

Drug(s) Affected By Suppressor of cytokine signaling 2 (SOCS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[46]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[46]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[50]

Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[53]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[56]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]

Drug(s) Affected By Unconventional myosin-Ib (MYO1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[62]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]

Drug(s) Affected By Kinesin heavy chain isoform 5C (KIF5C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[65]
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Haloperidol	DM96SE0	Delirium		Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[65]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[65]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]

Drug(s) Affected By Transcription factor Maf (MAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[69]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[70]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[71]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[39]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[72]

Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[73]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[73]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[73]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[74]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[75]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[77]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[78]

Drug(s) Affected By Tyrosine-protein kinase Lck (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[81]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[40]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[82]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[84]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[85]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]

Drug(s) Affected By Microtubule-associated protein 2 (MAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[87]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[89]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[90]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]

Drug(s) Affected By Plastin-2 (LCP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[92]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[93]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[95]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]

Drug(s) Affected By Kallikrein-2 (KLK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[98]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[100]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[101]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[102]

Drug(s) Affected By Phospholipase A2 group V (PLA2G5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Methamphetamine	DMPM4SK	Anxiety		Approved	[103]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[104]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
SB-203347	DM3AWMF	Discovery agent	N.A.	Investigative	[106]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[107]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[107]

Drug(s) Affected By Regulator of G-protein signaling 2 (RGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[108]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[109]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[111]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]

Drug(s) Affected By Retinaldehyde dehydrogenase 3 (ALDH1A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[114]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[115]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[117]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[117]

Drug(s) Affected By Selenoprotein P (SELENOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[108]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[119]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[120]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[50]

Drug(s) Affected By AF4/FMR2 family member 3 (AFF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[121]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[122]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]

Drug(s) Affected By Cysteine-rich secretory protein 3 (CRISP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[125]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[126]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[127]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]

Drug(s) Affected By Tumor protein D52 (TPD52)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[128]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[128]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[129]

Drug(s) Affected By Acyl-coenzyme A synthetase ACSM1, mitochondrial (ACSM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[125]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]

Drug(s) Affected By Ras GTPase-activating-like protein IQGAP2 (IQGAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[131]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[133]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[134]

Drug(s) Affected By Glycine N-methyltransferase (GNMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[135]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[136]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[135]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]

Drug(s) Affected By Ketimine reductase mu-crystallin (CRYM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[76]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[138]

Drug(s) Affected By Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase (ADPRM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[95]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]
CH-223191	DMMJZYC	Solid tumour/cancer	2A00-2F9Z	Investigative	[139]

Drug(s) Affected By Protein GREB1 (GREB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[140]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[141]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[141]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[143]
Mestranol	DMG3F94	Contraception	QA21	Approved	[141]

Drug(s) Affected By EF-hand calcium-binding domain-containing protein 12 (EFCAB12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[144]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[145]

Drug(s) Affected By Rho-related GTP-binding protein RhoU (RHOU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[78]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[147]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[148]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[148]

Drug(s) Affected By Transient receptor potential cation channel subfamily M member 8 (TRPM8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[149]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[149]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[135]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[150]

Drug(s) Affected By Alpha-protein kinase 2 (ALPK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[151]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[135]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[93]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[152]

Drug(s) Affected By Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial (AADAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[93]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[153]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[154]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[33]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]

Drug(s) Affected By Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[119]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]

Drug(s) Affected By Specifically androgen-regulated gene protein (C1ORF116)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[155]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[156]

Drug(s) Affected By ER degradation-enhancing alpha-mannosidase-like protein 3 (EDEM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[157]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[32]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[158]

Drug(s) Affected By Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[93]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[138]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[144]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]

Drug(s) Affected By Teneurin-1 (TENM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[108]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[160]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[160]

Drug(s) Affected By Transmembrane and coiled-coil domain protein 3 (TMCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[161]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[161]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[134]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[134]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[161]

Drug(s) Affected By E3 ubiquitin-protein ligase NEURL1B (NEURL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[162]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[138]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[134]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[163]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[164]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[151]

Drug(s) Affected By Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Bortezomib	DMNO38U	Leukemia		Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[86]
Isoflavone	DM7U58J	N. A.	N. A.	Phase 4	[166]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[167]

Drug(s) Affected By Integrin beta-1-binding protein 1 (ITGB1BP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Heroin diacetylmorphine	DMDBWHY	Neurological disorder	6B60	Approved	[168]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[169]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[170]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[171]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[86]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[86]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[172]

Drug(s) Affected By Sushi domain-containing protein 5 (SUSD5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[40]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[173]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[174]
methyl p-hydroxybenzoate	DMO58UW	Discovery agent	N.A.	Investigative	[175]

Drug(s) Affected By Polycomb protein EED (EED)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[176]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[177]
GSK2816126	DMJDVW4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[178]

Drug(s) Affected By Myc proto-oncogene protein (MYC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[179]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[180]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[181]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Selenium	DM25CGV	N. A.	N. A.	Approved	[183]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[184]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[185]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[186]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[108]

Drug(s) Affected By Amyloid-beta precursor protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[187]
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[108]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[188]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[190]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[191]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[192]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[193]

Drug(s) Affected By Annexin A4 (ANXA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[194]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[195]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[158]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[176]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[38]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[196]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[197]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[198]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[199]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[200]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[199]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[201]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[202]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[203]

Drug(s) Affected By Midkine (MDK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[158]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[204]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[205]

Drug(s) Affected By Hepatocyte nuclear factor 1-beta (HNF1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[206]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[208]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[209]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[144]

Drug(s) Affected By Small ribosomal subunit protein eS19 (RPS19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[131]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[210]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[211]
Bortezomib	DMNO38U	Leukemia		Approved	[212]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[213]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[214]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[215]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[216]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[217]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[218]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[219]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[220]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[221]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[222]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[223]

Drug(s) Affected By Neurogenic locus notch homolog protein 1 (NOTCH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[224]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[225]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[226]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[227]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[228]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[229]

Drug(s) Affected By Transcription factor SOX-9 (SOX9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[230]
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[231]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[232]

Drug(s) Affected By CCAAT/enhancer-binding protein alpha (CEBPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[74]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[233]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[234]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[235]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[236]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[236]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]

Drug(s) Affected By Hepatocyte nuclear factor 3-alpha (FOXA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[237]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[140]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[238]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[237]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[239]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]

Drug(s) Affected By Ubiquitin-ribosomal protein eS31 fusion protein (RPS27A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[240]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[241]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[65]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[242]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[134]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[243]

Drug(s) Affected By Protein jagged-1 (JAG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[244]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[245]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[31]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[152]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]

Drug(s) Affected By Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[246]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[247]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[248]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[249]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[250]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[251]

Drug(s) Affected By Neurogenic locus notch homolog protein 2 (NOTCH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[252]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[253]
Bortezomib	DMNO38U	Leukemia		Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[254]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[76]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[86]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[255]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[256]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[257]

Drug(s) Affected By SNW domain-containing protein 1 (SNW1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[258]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[171]
G1	DMTV42K	Lymphoma	2A80-2A86	Phase 1/2	[258]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[259]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[260]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[167]

Drug(s) Affected By Transcription factor HES-1 (HES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[261]
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]

Drug(s) Affected By Polycomb protein SUZ12 (SUZ12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[262]
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[112]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[151]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[263]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[32]

Drug(s) Affected By Probable E3 ubiquitin-protein ligase DTX2 (DTX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]

Drug(s) Affected By E3 ubiquitin-protein ligase MIB1 (MIB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[264]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[154]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]

Drug(s) Affected By NF-kappa-B-activating protein (NKAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[259]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[265]

Drug(s) Affected By Probable E3 ubiquitin-protein ligase DTX3 (DTX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[266]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[260]

Drug(s) Affected By Polypeptide N-acetylgalactosaminyltransferase 11 (GALNT11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[267]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[93]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[20]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[171]

Drug(s) Affected By Gamma-secretase subunit APH-1B (APH1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[25]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[148]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[148]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]

Drug(s) Affected By Nicastrin (NCSTN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[39]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[269]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[270]

Drug(s) Affected By Mastermind-like protein 1 (MAML1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Napabucasin	DMDZ6Q3	Colorectal cancer	2B91.Z	Phase 3	[271]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[177]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[259]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[260]

Drug(s) Affected By E3 ubiquitin-protein ligase MIB2 (MIB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[272]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[95]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[23]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[79]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[151]

Drug(s) Affected By p53 apoptosis effector related to PMP-22 (PERP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[273]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[274]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[153]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[157]

Drug(s) Affected By E3 ubiquitin-protein ligase Itchy homolog (ITCH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[58]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[171]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
Torcetrapib	DMDHYM7	Hyperlipidaemia	5C80	Discontinued in Phase 2	[275]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[79]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[276]

Drug(s) Affected By Mastermind-like protein 3 (MAML3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[174]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[77]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[137]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[145]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[79]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[151]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[174]

Drug(s) Affected By Intraflagellar transport protein 74 homolog (IFT74)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[277]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[157]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[254]

Drug(s) Affected By RNA-binding protein 15 (RBM15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[262]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[259]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Indomethacin	DMSC4A7	Bursitis		Approved	[278]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[279]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[242]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[76]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]

Drug(s) Affected By Msx2-interacting protein (SPEN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[280]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[264]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[174]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[95]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]

Drug(s) Affected By GDP-fucose protein O-fucosyltransferase 1 (POFUT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[63]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[170]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[281]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[282]
chloropicrin	DMSGBQA	Discovery agent	N.A.	Investigative	[283]

Drug(s) Affected By Notchless protein homolog 1 (NLE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[76]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[205]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[242]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[171]

Drug(s) Affected By Gamma-secretase subunit PEN-2 (PSENEN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[242]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[284]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[276]

Drug(s) Affected By Protein sel-1 homolog 1 (SEL1L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[155]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[232]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[205]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[134]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[76]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[3]

Drug(s) Affected By Intraflagellar transport protein 172 homolog (IFT172)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[285]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[79]

Drug(s) Affected By Neurogenic locus notch homolog protein 3 (NOTCH3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[286]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[93]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[287]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[144]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
UNC0379	DMD1E4J	Hepatocellular carcinoma	2C12.02	Preclinical	[288]

Drug(s) Affected By Protein jagged-2 (JAG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[289]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[95]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[290]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[21]
PEITC	DMOMN31	Prostate cancer	2C82.0	Phase 2	[291]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[145]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[292]

Drug(s) Affected By E3 ubiquitin-protein ligase DTX4 (DTX4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[293]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[27]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[105]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[281]

Drug(s) Affected By Epsin-1 (EPN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[47]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[37]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[65]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[95]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[22]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[259]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[163]
chloropicrin	DMSGBQA	Discovery agent	N.A.	Investigative	[283]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acyl-coenzyme A synthetase ACSM1, mitochondrial (ACSM1)	OT1TS9M9	ACSM1_HUMAN	Gene/Protein Processing	[3]
AF4/FMR2 family member 3 (AFF3)	OTR0705Z	AFF3_HUMAN	Gene/Protein Processing	[3]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1)	OT3JQD99	SIA7A_HUMAN	Gene/Protein Processing	[3]
Alpha-protein kinase 2 (ALPK2)	OTWZZDQ9	ALPK2_HUMAN	Gene/Protein Processing	[3]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Gene/Protein Processing	[4]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Gene/Protein Processing	[4]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Gene/Protein Processing	[3]
Bone morphogenetic protein receptor type-1B (BMPR1B)	OTGFN0OD	BMR1B_HUMAN	Gene/Protein Processing	[3]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Gene/Protein Processing	[4]
Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1)	OTBML9D9	CGAT1_HUMAN	Gene/Protein Processing	[3]

References

• [1] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [4] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [5] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [6] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [9] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [10] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [11] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [14] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [15] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [16] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [17] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [18] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [19] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [20] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [21] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [22] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [23] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [24] The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.
• [25] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [26] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [27] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [28] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [29] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [30] Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect. 2007 Nov;115(11):1646-53. doi: 10.1289/ehp.10283.
• [31] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [32] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [33] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [34] Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
• [35] Identification of differentially expressed genes in hepatic HepG2 cells treated with acetaminophen using suppression subtractive hybridization. Biol Pharm Bull. 2005 Jul;28(7):1148-53. doi: 10.1248/bpb.28.1148.
• [36] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [37] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [38] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [39] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [40] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [41] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [42] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [43] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [44] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [45] The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
• [46] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [47] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [48] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [49] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [50] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [51] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [52] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [53] ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
• [54] Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
• [55] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [56] Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
• [57] Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.
• [58] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [59] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [60] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [61] Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
• [62] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [63] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [64] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [65] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [66] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [67] Effect of mood stabilizers on gene expression in lymphoblastoid cells. J Neural Transm (Vienna). 2010 Feb;117(2):155-64.
• [68] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [69] Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
• [70] A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec;3(12):e486. doi: 10.1371/journal.pmed.0030486.
• [71] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [72] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [73] Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
• [74] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [75] Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
• [76] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [77] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [78] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [79] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [80] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [81] Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
• [82] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [83] Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
• [84] Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
• [85] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
• [86] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [87] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [88] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [89] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [90] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [91] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [92] Androgen receptor modulation following combination exposure to brominated flame-retardants. Sci Rep. 2018 Mar 19;8(1):4843. doi: 10.1038/s41598-018-23181-0.
• [93] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [94] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [95] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [96] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [97] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [98] Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem. 2002 Dec 13;277(50):48366-71. doi: 10.1074/jbc.M209074200. Epub 2002 Oct 9.
• [99] Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells. Prostate. 2019 Feb;79(2):140-150. doi: 10.1002/pros.23719. Epub 2018 Oct 2.
• [100] Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
• [101] Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11.
• [102] Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
• [103] Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
• [104] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [105] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [106] Characteristics of arachidonic acid generation in human basophils: relationship between the effects of inhibitors of secretory phospholipase A2 activity and leukotriene C4 release. J Pharmacol Exp Ther. 1998 Mar;284(3):847-57.
• [107] Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem. 2002 Feb 15;277(7):5061-73. doi: 10.1074/jbc.M109083200. Epub 2001 Dec 6.
• [108] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [109] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [110] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [111] Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin. 2003 Jul;24(7):646-50.
• [112] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [113] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [114] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [115] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [116] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [117] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [118] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [119] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [120] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [121] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [122] Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells. Toxins (Basel). 2023 Feb 9;15(2):140. doi: 10.3390/toxins15020140.
• [123] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [124] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [125] Arsenic alters transcriptional responses to Pseudomonas aeruginosa infection and decreases antimicrobial defense of human airway epithelial cells. Toxicol Appl Pharmacol. 2017 Sep 15;331:154-163.
• [126] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [127] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [128] Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
• [129] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [130] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [131] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [132] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [133] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [134] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [135] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [136] Use of transcriptomics in hazard identification and next generation risk assessment: A case study with clothianidin. Food Chem Toxicol. 2022 Aug;166:113212. doi: 10.1016/j.fct.2022.113212. Epub 2022 Jun 8.
• [137] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [138] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [139] Adaptive changes in global gene expression profile of lung carcinoma A549 cells acutely exposed to distinct types of AhR ligands. Toxicol Lett. 2018 Aug;292:162-174.
• [140] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [141] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [142] Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
• [143] Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
• [144] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [145] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [146] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [147] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [148] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [149] The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
• [150] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [151] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [152] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [153] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [154] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [155] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [156] A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015 Jun 1;285(2):79-88.
• [157] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [158] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [159] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [160] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [161] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [162] Differently expressed long noncoding RNAs and mRNAs in TK6 cells exposed to low dose hydroquinone. Oncotarget. 2017 Oct 4;8(56):95554-95567. doi: 10.18632/oncotarget.21481. eCollection 2017 Nov 10.
• [163] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [164] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [165] Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J. 2005 Sep;19(11):1522-4. doi: 10.1096/fj.04-3619fje. Epub 2005 Jun 21.
• [166] Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. J Nutr. 2007 Apr;137(4):964-72.
• [167] Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
• [168] Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. Neuropsychopharmacology. 2006 Oct;31(10):2304-12. doi: 10.1038/sj.npp.1301089. Epub 2006 May 3.
• [169] Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin. J Neurochem. 2004 Mar;88(5):1211-9. doi: 10.1046/j.1471-4159.2003.02247.x.
• [170] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [171] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [172] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [173] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [174] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [175] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.
• [176] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [177] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [178] Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer. Toxicol Appl Pharmacol. 2020 Oct 1;404:115200. doi: 10.1016/j.taap.2020.115200. Epub 2020 Aug 14.
• [179] Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci. 2002 Apr;66(2):233-43. doi: 10.1093/toxsci/66.2.233.
• [180] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [181] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [182] ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
• [183] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [184] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [185] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [186] Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
• [187] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [188] Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
• [189] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [190] Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
• [191] Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
• [192] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [193] Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
• [194] Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
• [195] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [196] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [197] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [198] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [199] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [200] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [201] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [202] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [203] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [204] Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun. 2004 Feb 13;314(3):661-6. doi: 10.1016/j.bbrc.2003.12.146.
• [205] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [206] Gestational bisphenol A exposure induces fatty liver development in male offspring mice through the inhibition of HNF1b and upregulation of PPAR. Cell Biol Toxicol. 2021 Feb;37(1):65-84. doi: 10.1007/s10565-020-09535-3. Epub 2020 Jul 4.
• [207] Molecular characterization of a toxicological tipping point during human stem cell differentiation. Reprod Toxicol. 2020 Jan;91:1-13. doi: 10.1016/j.reprotox.2019.10.001. Epub 2019 Oct 7.
• [208] Folic acid modulates cancer-associated micro RNAs and inflammatory mediators in neoplastic and non-neoplastic colonic cells in a different way. Mol Nutr Food Res. 2017 Dec;61(12). doi: 10.1002/mnfr.201700260. Epub 2017 Nov 9.
• [209] Effects of resveratrol on gene expression in renal cell carcinoma. Cancer Biol Ther. 2004 Sep;3(9):882-8. doi: 10.4161/cbt.3.9.1056. Epub 2004 Sep 21.
• [210] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [211] Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
• [212] Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004 Nov;24(22):9695-704. doi: 10.1128/MCB.24.22.9695-9704.2004.
• [213] Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data. Toxicol Sci. 2018 May 1;163(1):182-195. doi: 10.1093/toxsci/kfy012.
• [214] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [215] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [216] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [217] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [218] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [219] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [220] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [221] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [222] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [223] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [224] Quercetin attenuates cell apoptosis of oxidant-stressed SK-N-MC cells while suppressing up-regulation of the defensive element, HIF-1alpha. Neuroscience. 2014 Sep 26;277:780-93.
• [225] Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci. 2012;13(8):9627-9641. doi: 10.3390/ijms13089627. Epub 2012 Aug 2.
• [226] Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway. Chem Biol Interact. 2018 Oct 1;294:28-33. doi: 10.1016/j.cbi.2018.08.018. Epub 2018 Aug 18.
• [227] The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem. 2009 Mar 1;106(4):682-92. doi: 10.1002/jcb.22065.
• [228] Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. Toxicol Appl Pharmacol. 2020 Jun 1;396:115001. doi: 10.1016/j.taap.2020.115001. Epub 2020 Apr 8.
• [229] PLK1 targets NOTCH1 during DNA damage and mitotic progression. J Biol Chem. 2019 Nov 22;294(47):17941-17950. doi: 10.1074/jbc.RA119.009881. Epub 2019 Oct 9.
• [230] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [231] The aryl hydrocarbon receptor activates the retinoic acid receptoralpha through SMRT antagonism. Biochimie. 2006 Mar-Apr;88(3-4):387-97. doi: 10.1016/j.biochi.2005.11.007. Epub 2005 Dec 7.
• [232] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [233] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [234] C/EBPalpha inactivation in FAK-overexpressed HL-60 cells impairs cell differentiation. Cell Signal. 2006 Jul;18(7):955-63. doi: 10.1016/j.cellsig.2005.08.014. Epub 2005 Oct 14.
• [235] Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):204-9. doi: 10.1093/abbs/gmq130. Epub 2011 Jan 21.
• [236] Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
• [237] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [238] Activation of PPAR and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One. 2020 Aug 21;15(8):e0237976. doi: 10.1371/journal.pone.0237976. eCollection 2020.
• [239] Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic. Oncotarget. 2015 Aug 28;6(25):21493-506. doi: 10.18632/oncotarget.4085.
• [240] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [241] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [242] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [243] Nicotine Promotes Human Papillomavirus (HPV)-Immortalized Cervical Epithelial Cells (H8) Proliferation by Activating RPS27a-Mdm2-P53 Pathway In Vitro. Toxicol Sci. 2019 Feb 1;167(2):408-418. doi: 10.1093/toxsci/kfy246.
• [244] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [245] How benzene and its metabolites affect human marrow derived mesenchymal stem cells. Toxicol Lett. 2012 Oct 17;214(2):145-53. doi: 10.1016/j.toxlet.2012.08.015. Epub 2012 Aug 30.
• [246] Hydroquinone-induced miR-122 down-regulation elicits ADAM17 up-regulation, leading to increased soluble TNF- production in human leukemia cells with expressed Bcr/Abl. Biochem Pharmacol. 2013 Sep 1;86(5):620-31. doi: 10.1016/j.bcp.2013.06.009. Epub 2013 Jun 20.
• [247] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [248] The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004 Jan;19(1):147-54. doi: 10.1359/jbmr.2004.19.1.147.
• [249] Extremely low copper concentrations affect gene expression profiles of human prostate epithelial cell lines. Chem Biol Interact. 2010 Oct 6;188(1):214-9.
• [250] Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci. 2001 Jan;59(1):185-92.
• [251] Effect of ovarian steroids on gene expression profile in human uterine microvascular endothelial cells. Fertil Steril. 2009 Aug;92(2):709-21.
• [252] Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines. Differentiation. 2012 Nov;84(4):330-43. doi: 10.1016/j.diff.2012.07.006. Epub 2012 Aug 18.
• [253] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [254] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [255] Evaluation of gene expression changes in human primary lung epithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide. Environ Mol Mutagen. 2015 Jun;56(5):477-90. doi: 10.1002/em.21937. Epub 2015 Apr 14.
• [256] A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thromb Res. 2012 Jul;130(1):45-51. doi: 10.1016/j.thromres.2011.12.009. Epub 2012 Jan 2.
• [257] Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
• [258] The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. Toxicol Sci. 2016 Jun;151(2):434-46. doi: 10.1093/toxsci/kfw057. Epub 2016 Mar 29.
• [259] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [260] Glyphosate-based herbicides at low doses affect canonical pathways in estrogen positive and negative breast cancer cell lines. PLoS One. 2019 Jul 11;14(7):e0219610. doi: 10.1371/journal.pone.0219610. eCollection 2019.
• [261] Modulation of notch signaling pathway to prevent H2O2/menadione-induced SK-N-MC cells death by EUK134. Cell Mol Neurobiol. 2014 Oct;34(7):1037-45. doi: 10.1007/s10571-014-0079-0. Epub 2014 Jul 9.
• [262] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [263] Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol. 2008 Sep;39(3):312-23. doi: 10.1165/rcmb.2008-0012OC. Epub 2008 Apr 17.
• [264] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [265] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [266] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [267] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [268] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [269] The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci. 2007 Feb 7;27(6):1247-54. doi: 10.1523/JNEUROSCI.5320-06.2007.
• [270] gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009 Jan 15;69(2):573-82. doi: 10.1158/0008-5472.CAN-08-2088.
• [271] Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
• [272] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [273] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [274] Characterisation of cisplatin-induced transcriptomics responses in primary mouse hepatocytes, HepG2 cells and mouse embryonic stem cells shows conservation of regulating transcription factor networks. Mutagenesis. 2014 Jan;29(1):17-26.
• [275] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
• [276] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [277] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [278] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [279] Role of N6-methyladenosine RNA modification in the imbalanced inflammatory homeostasis of arsenic-induced skin lesions. Environ Toxicol. 2022 Aug;37(8):1831-1839. doi: 10.1002/tox.23530. Epub 2022 Apr 1.
• [280] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [281] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [282] Isobaric tags for relative and absolute quantitation-based proteomics analysis of the effect of ginger oil on bisphenol A-induced breast cancer cell proliferation. Oncol Lett. 2021 Feb;21(2):101. doi: 10.3892/ol.2020.12362. Epub 2020 Dec 8.
• [283] Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
• [284] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [285] New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
• [286] Prediction of the contact sensitizing potential of chemicals using analysis of gene expression changes in human THP-1 monocytes. Toxicol Lett. 2010 Nov 10;199(1):51-9.
• [287] Effects of residual levels of tetracycline on the barrier functions of human intestinal epithelial cells. Food Chem Toxicol. 2017 Nov;109(Pt 1):253-263. doi: 10.1016/j.fct.2017.09.004. Epub 2017 Sep 4.
• [288] Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma. Cancer Cell. 2017 Jan 9;31(1):50-63.
• [289] Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Cancer Cell Int. 2013 Mar 13;13(1):25. doi: 10.1186/1475-2867-13-25.
• [290] Gamma-irradiation and doxorubicin treatment of normal human cells cause cell cycle arrest via different pathways. Mol Cells. 2005 Dec 31;20(3):331-8.
• [291] Notch activation by phenethyl isothiocyanate attenuates its inhibitory effect on prostate cancer cell migration. PLoS One. 2011;6(10):e26615. doi: 10.1371/journal.pone.0026615. Epub 2011 Oct 24.
• [292] Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure. Int J Oncol. 2012 Jul;41(1):369-77.
• [293] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.